{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.4","upperLimit":"95.4","value":"88.9"},{"groupId":"OG001","lowerLimit":"88.4","upperLimit":"98.5","value":"93.4"}]}],"title":"OS Rate at 6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62.7","upperLimit":"81.3","value":"72.0"},{"groupId":"OG001","lowerLimit":"75.8","upperLimit":"91.1","value":"83.5"}]}],"title":"OS Rate at 12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.5","upperLimit":"71.8","value":"61.7"},{"groupId":"OG001","lowerLimit":"64.2","upperLimit":"82.5","value":"73.3"}]}],"title":"OS Rate at 18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.9","upperLimit":"68.5","value":"58.2"},{"groupId":"OG001","lowerLimit":"57.8","upperLimit":"77.2","value":"67.5"}]}],"title":"OS Rate at 24 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.2","upperLimit":"62.4","value":"51.8"},{"groupId":"OG001","lowerLimit":"52.7","upperLimit":"72.9","value":"62.8"}]}],"title":"OS Rate at 36 months"},{"categories":[{"measurements":[{"comment":"Only percentage of participants who died to be reported","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"45.7"},{"comment":"Only percentage of participants who died to be reported","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"37.0"}]}],"title":"Participants who died"},{"categories":[{"measurements":[{"comment":"Only percentage of participants who were censored to be reported","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"54.3"},{"comment":"Only percentage of participants who were censored to be reported","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"63.0"}]}],"title":"Participants who were censored"}],"denoms":[{"counts":[{"groupId":"OG000","value":"92"},{"groupId":"OG001","value":"92"}],"units":"Participants"}],"description":"Overall Survival (OS) rate is defined as the percentage of participants alive at fixed timepoints. OS is defined as the time from randomization to death due to any cause. Participants alive or lost to follow up at the time of analysis will be censored at the last date the participants was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"3 cycles of standard of care (SOC) salvage therapy (R-DHAP, R-ICE and R-GDP) per physician's choice. Participants responding to SOC are expected to undergo high dose chemotherapy (HDCT) and hematopoietic stem cell transplant (HSCT). If requested by the investigator, participants may be allowed to receive JCAR017 upon meeting progression, relapse, or suboptimal response. 1 cycle = 3 weeks","id":"OG000","title":"Standard of Care Arm"},{"description":"\\[Lymphodepleting chemotherapy (LDC)\\] Fludarabine IV (30 mg/m\\^2/day for 3 days) and cyclophosphamide IV (300 mg/m\\^2/day for 3 days) followed by JCAR017 IV infusion at a dose of 100 x 10\\^6 JCAR017-positive viable transduced T cells (CAR+ T cells) on Day 29 (2 to 7 days after completion of LD chemotherapy)","id":"OG001","title":"Liso-cel Arm"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Months 6, 12, 18, 24, 36","title":"Overall Survival (OS) Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}